# CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers

> **NCT06548412** · PHASE1,PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 50 (estimated)

## Conditions studied

- Metastatic Biliary Tract Cancer

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Cisplatin
- **DRUG:** Durvalumab
- **DRUG:** CTX-009

## Key facts

- **NCT ID:** NCT06548412
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-22
- **Primary completion:** 2027-05-01
- **Final completion:** 2029-05-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-01-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06548412

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06548412, "CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06548412. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*